A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors

Journal of Controlled Release

Volumn 142, Issue 1, 2010, Pages 14-21

  Briganti, Enrica ^a   Spiller, Dario ^a   Mirtelli, Chiara ^a   Kull, Silvia ^a   Counoupas, Claudio ^b   Losi, Paola ^a   Senesi, Sonia ^b   Di Stefano, Rossella ^b   Soldani, Giorgio ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

BFGF; Composite scaffold; Delivery system; Fibrin; VEGF

Indexed keywords

ANGIOGENESIS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL ACTIVITIES; BIOLOGICAL POLYMERS; COLOCALIZATION; COMPOSITE SCAFFOLDS; CONTROLLED DELIVERY; DELIVERY SYSTEMS; ELISA ASSAY; FIBRIN-BASED SCAFFOLDS; FIBRINOGEN CONCENTRATION; GROWTH FACTOR; HEPARIN BINDING; IN-VITRO; ISCHEMIC TISSUES; MANUFACTURING PROCESS; MECHANICAL STRENGTH; MRNA EXPRESSION; PHASE INVERSION; SUSTAINED RELEASE; SYNTHETIC MATERIALS; TEMPORAL DISTRIBUTION; TENSILE TESTS;

BIOACTIVITY; BIOPOLYMERS; ETHERS; EVOLUTIONARY ALGORITHMS; GENE EXPRESSION; MECHANICAL PROPERTIES; PEPTIDES; POLYSACCHARIDES; SILICONES; TENSILE TESTING;

SCAFFOLDS;

ANGIOGENIC FACTOR; DIMETICONE; FIBRIN; HEPARIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MESSENGER RNA; POLYETHERURETHAN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT VASCULOTROPIN 165; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BIOCOMPATIBILITY; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG MANUFACTURE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MECHANICAL STIMULATION; MICROSCOPY; MONOCYTE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TENSILE STRENGTH; UMBILICAL VEIN; YOUNG MODULUS;

ANGIOGENESIS INDUCING AGENTS; CELL LINE; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DIMETHYLPOLYSILOXANES; ELASTIC MODULUS; ENDOTHELIAL CELLS; FIBRIN; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMANS; MATERIALS TESTING; MONOCYTES; POLYURETHANES; SURFACE PROPERTIES; TISSUE SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749119802     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.09.029     Document Type: Article

References (47)

1. Fukuda S., Yoshii S., Kaga S., Matsumoto M., Kugiyama K., Maulik N. Angiogenic strategy for human ischemic heart disease: brief overview. Mol. Cell. Biochem. 2004, 264:143-149.
2. Bennett S.P., Griffiths G.D., Schor A.M., Leese G.P., Schor S.L. Growth factors in the treatment of diabetic foot ulcers. Br. J. Surg. 2003, 90:133-146.
3. Hughes G.C., Biswas S.S., Yin B., Coleman R.E., DeGrado T.R., Landolfo C.K., Lowe J.E., Annex B.H., Landolfo K.P. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann. Thorac. Surg. 2004, 77:812-818.
4. Hasegawa T., Kimura A., Miyataka M., Inagaki M., Ishikawa K. Basic fibroblast growth factor increases regional myocardial blood flow and salvages myocardium in the infarct border zone in a rabbit model of acute myocardial infarction. Angiology 1999, 50(6):487-495.
5. Ruel M., Laham R.J., Parker J.A., Post M.J., Ware J.A., Simons M., Sellke F.W. Long-term effects of surgical angiogenic therapy with FGF2 protein. J. Thorac. Cardiovasc. Surg. 2002, 124(1):28-34.
6. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., Schatz R.A., Asahara T., Isner J.M., Kuntz R.E. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105(17):2012-2018.
7. Okumura M., Okuda T., Nakamura T., Yajima M. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol. Pharm. Bull. 1996, 19:530-535.
8. Wilcke I., Lohmeyer J.A., Liu S., Condurache A., Krüger S., Mailänder P., Machens H.G. VEGF(165) and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo. Langenbecks Arch. Surg. 2007, 392:305-314.
9. Robson M.C., Phillips L.G., Lawrence W.T., Bishop J.B., Youngerman J.S., Hayward P.G., Broemeling L.D., Heggers J.P. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann. Surg. 1992, 216(4):401-406.
10. Gibran N.S., Isik F.F., Heimbach D.M., Gordon D. Basic fibroblast growth factor in the early human burn wound. J. Surg. Res. 1994, 56(3):226-234.
11. Lee K.Y., Peters M.C., Mooney D.J. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J. Control. Release 2003, 87:49-56.
12. Sakiyama-Elbert S.E., Hubbell J.A. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J. Control. Release 2000, 69(1):149-158.
13. Sahni A., Odrljin T., Francis C.W. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J. Biol. Chem. 1998, 273:7554-7559.
14. Wong C., Inman E., Spaethe R., Helgerson S. Fibrin-based biomaterials to deliver human growth factors. Thromb. Haemost. 2003, 89:573-582.
15. Sahni A., Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000, 96:3772-3778.
16. 165 release from a sprayed fibrin biomatrix induces angiogenesis, up-regulation of endogenous VEGF-R2, and reduces ischemic flap necrosis. Wound Repair Regen. 2008, 16:542-550.
17. Giannoni P., Hunziker E.B. Release kinetics of transforming growth factor-beta1 from fibrin clots. Biotechnol. Bioeng. 2003, 83(1):121-123.
18. Jeon O., Ryu S.H., Chung J.H., Kim B. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control. Release 2005, 105:249-259.
19. Briganti E., Losi P., Raffi A., Scoccianti M., Munaò A., Soldani G. Silicone based polyurethane materials: a promising biocompatible elastomeric formulation for cardiovascular applications. J. Mater. Sci., Mater. Med. 2006, 17(3):259-266.
20. Soldani G., Bernabei M., Losi P., Crucean A., Chiappino D., Burchielli S., Bernini F. In vitro experiments and in vivo implants to evaluate a new silicone-based polyurethane material for replacement of small vessels. Cardiol. Young 2004, 3:20-23.
21. G. Soldani, Elastomeric material and process for preparation thereof, U.S. Patent 7, 157, 118 B2, 2nd January, 2007.
22. Soldani G., Panol G., Sasken H.F., Goddard M.B., Galletti P.M. Small diameter polyurethane-polydimethylsiloxane vascular prostheses made by a spraying, phase-inversion process. J. Mater. Sci., Mater. Med. 1992, 3:106-113.
23. Okoshi T., Chen H., Soldani G., Galletti P.M., Goddard M. Microporous small diameter PVDF-TrFE vascular grafts fabricated by a spray phase inversion technique. ASAIO J. 1992, 38:M201-M206.
24. Jaffe E.A., Nachman R.L., Becher C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 1973, 52:2745-2756.
25. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9):2002-2007.
26. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18(1):4-25.
27. Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFR beta signaling. J. Cell Sci. 2005, 118:3759-3768.
28. Asahara T., Bauters C., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
29. van Hinsbergh V., Collen A., Koolwijk P. Role of fibrin matrix in angiogenesis. Ann. N. Y. Acad. Sci. 2001, 936:426-437.
30. Srinivasan S., Dollin M., McAllum P., Berger Y., Rootman D.S., Slomovic A.R. Fibrin glue versus sutures for attaching the conjunctival autograft in pterygium surgery: a prospective observer masked clinical trial. Br. J. Ophthalmol. 2009, 93(2):215-218.
31. Neuss H., Raue W., Koplin G., Schwenk W., Reetz C., Mall J.W. A prospective randomized trial: The influence of intraoperative application of fibrin glue after radical inguinal/iliacal lymph node dissection on postoperative morbidity. Eur. J. Surg. Oncol. 2009, 35(8):884-889.
32. Hausner T., Schmidhammer R., Zandieh S., Hopf R., Schultz A., Gogolewski S., Hertz H., Redl H. Nerve regeneration using tubular scaffolds from biodegradable polyurethane. Acta Neurochir. Suppl. 2007, 100:69-72.
33. Spiller D., Losi P., Briganti E., Sbrana S., Kull S., Martinelli I., Soldani G. PDMS content affects in vitro hemocompatibility of synthetic vascular grafts. J. Mater. Sci., Mater. Med. 2007, 18(6):1097-1104.
34. Okoshi T., Goddard M., Galletti P.M., Soldani G. In vivo evaluation of porous versus skinned polyurethane-polydimethylsiloxane small diameter vascular grafts. ASAIO Trans. 1991, 37(3):M480-M481.
35. Ryan E.A., Mockros L.F., Weisel J.W., Lorand L. Structural origins of fibrin clot rheology. Biophys. J. 1999, 77(5):2813-2826.
36. Carr M.E., Carr S.L. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. Blood Coagul. Fibrinolysis 1995, 6(1):79-86.
37. Herbert C.B., Nagaswami C., Bittner G.D., Hubbell J.A., Weisel J.W. Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels. J. Biomed. Mater. Res. 1998, 40(4):551-559.
38. Tabata Y., Hijikata S., Ikada Y. Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels. J. Control. Release 1994, 31:189-199.
39. Deblois C., Cote M.F., Doilon C.J. Heparin-fibroblast growth factor fibrin complex: in vitro and in vivo applications to collagen-based materials. Biomaterials 1994, 15:665-672.
40. Tabata Y., Yamada K., Miyamoto S., Nagata I., Kikuchi H., Aoyama I., Tamura M., Ikada Y. Bone regeneration by basic fibroblast growth factor complexed with biodegradable hydrogels. Biomaterials 1998, 19:807-815.
41. Bhang S.H., Jeon O., Choi C.Y., Kwon Y.H., Kim B.S. Controlled release of nerve growth factor from fibrin gel. J. Biomed. Mater. Res. A 2007, 80(4):998-1002.
42. Janmey P.A., Winer J.P., Weisel J.W. Fibrin gels and their clinical and bioengineering applications. J. R. Soc. Interface 2009, 6:1-10.
43. Lobb R., Sasse J., Sullivan R., Shing Y., D'Amore P., Jacobs J., Klagsbrun M. Purification and characterization of heparin-binding endothelial cell growth factors. J. Biol. Chem. 1986, 261(4):1924-1928.
44. Taylor S.J., Sakiyama-Elbert S.E. Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model. J. Control. Release 2006, 116(2):204-210.
45. Walker A., Turnbull J.E., Gallagher J.T. Specific heparin sulfate saccharides mediated the activity of basic fibroblast growth factor. J. Biol. Chem. 1994, 269:931-935.
46. Mukaida N., Harada A., Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998, 9(1):9-23.
47. Smits L., Ozolanta I., Ozolins V., Lacis A., Kasyanov V. NBC-14th Nordic-Baltic Conference on Biomedical Engineering and Medical Physics 2008, vol. 20:76-79. Springer, Berlin.